Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study


GRACE met its primary endpoint 

Significant improvements in hypertension, hyperglycemia, and other manifestations of cortisol excess were observed throughout the treatment with relacorilant

Due to relacorilant’s specificity for the glucocorticoid receptor and its unique mechanism of action, the observed efficacy was seen: Without cases of relacorilant-induced irregular vaginal bleeding with endometrial hypertrophy 

Without increases in cortisol concentrations and relacorilant-induced hypokalemia

Without reported cases of adrenal insufficiency 

Without independently-confirmed QT prolongation

Download Presentation